Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
EWTX on Nasdaq
Shares outstanding
105,337,747
Price per share
$24.82
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
111,964,031
Total reported value
$1,816,272,346
% of total 13F portfolios
0%
Share change
-6,779,934
Value change
-$102,065,530
Number of holders
171
Price from insider filings
$24.82
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 14% $234,894,152 15,252,867 ORBIMED ADVISORS LLC 09 May 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $169,149,248 10,428,437 RA Capital Management, L.P. 30 Sep 2025
BAKER BROS. ADVISORS LP 6.9% $95,196,398 7,305,940 Baker Bros. Advisors LP 30 Jun 2025
BlackRock, Inc. 5.5% $76,363,411 5,824,866 BlackRock, Inc. 30 Jun 2025
JANUS HENDERSON GROUP PLC 4.7% -10% $80,764,749 -$8,499,572 4,979,331 -9.5% JANUS HENDERSON GROUP PLC 30 Sep 2025
Paradigm Biocapital Advisors LP 5% $72,979,507 4,738,929 Paradigm BioCapital Advisors LP 27 Jan 2025
PERCEPTIVE ADVISORS LLC 4.4% -28% $60,458,535 -$22,875,429 4,639,949 -27% Perceptive Advisors LLC 30 Jun 2025

As of 30 Sep 2025, 171 institutional investors reported holding 111,964,031 shares of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX). This represents 106% of the company’s total 105,337,747 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) together control 92% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 15% 15,518,492 0% 6% $251,709,940
RA CAPITAL MANAGEMENT, L.P. 9.9% 10,428,437 +5.3% 2.1% $169,149,248
BAKER BROS. ADVISORS LP 6.9% 7,305,940 0% 0.86% $118,502,347
BlackRock, Inc. 6% 6,351,487 -6.3% 0% $103,021,118
Paradigm Biocapital Advisors LP 5.9% 6,170,131 +0.45% 3% $100,079,525
NOVO HOLDINGS A/S 5.1% 5,350,000 0% 5.6% $86,777,000
BRAIDWELL LP 4.9% 5,210,831 0% 2.5% $84,519,679
JANUS HENDERSON GROUP PLC 4.7% 4,979,331 -9.5% 0.04% $80,804,202
VANGUARD GROUP INC 4.6% 4,803,941 -0.78% 0% $77,919,924
Cormorant Asset Management, LP 3.8% 4,010,000 -5.7% 4.5% $65,042,200
Siren, L.L.C. 3.7% 3,897,099 +23% 2.5% $63,210,946
PERCEPTIVE ADVISORS LLC 3.6% 3,795,894 -18% 1.8% $61,569,401
Bellevue Group AG 2.6% 2,775,997 0% 0.94% $45,026,671
Driehaus Capital Management LLC 2.1% 2,228,285 +6% 0.26% $36,142,783
MPM BIOIMPACT LLC 1.6% 1,720,741 0% 4.6% $27,910,419
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,717,641 -4.4% 0% $27,864,280
STATE STREET CORP 1.6% 1,699,909 -4.6% 0% $27,572,524
Integral Health Asset Management, LLC 1.4% 1,500,000 +50% 1.8% $24,330,000
First Light Asset Management, LLC 1.3% 1,414,994 -17% 2.2% $22,951,203
DIMENSIONAL FUND ADVISORS LP 1.1% 1,183,136 +13% 0% $19,187,177
AMERICAN CENTURY COMPANIES INC 1% 1,095,473 +40% 0.01% $17,768,606
New Leaf Venture Partners, L.L.C. 0.98% 1,030,161 0% 39% $16,709,211
MORGAN STANLEY 0.83% 869,678 +20% 0% $14,106,178
DEERFIELD MANAGEMENT COMPANY, L.P. 0.73% 765,694 -63% 0.19% $12,419,557
MILLENNIUM MANAGEMENT LLC 0.69% 725,425 -21% 0.01% $11,766,394

Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 914,414 $22,691,523 +$6,978,123 $24.82 10
2025 Q3 111,964,031 $1,816,272,346 -$102,065,530 $16.22 171
2025 Q2 118,737,861 $1,557,153,070 +$135,315,946 $13.11 177
2025 Q1 105,289,941 $2,320,227,206 +$130,326,516 $22.00 190
2024 Q4 98,918,436 $2,640,722,866 -$78,891,260 $26.70 197
2024 Q3 101,289,495 $2,703,865,523 -$12,073,061 $26.69 174
2024 Q2 101,617,706 $1,830,101,707 +$179,027,088 $18.01 138
2024 Q1 91,602,360 $1,670,777,013 +$311,144,088 $18.24 126
2023 Q4 79,647,397 $871,350,413 +$122,344,417 $10.94 115
2023 Q3 68,438,296 $392,172,292 -$8,215,044 $5.73 84
2023 Q2 69,494,963 $538,802,876 +$23,832,932 $7.75 94
2023 Q1 66,455,672 $443,090,314 -$748,812 $6.67 85
2022 Q4 66,466,915 $594,208,237 +$17,736,112 $8.94 90
2022 Q3 64,390,889 $633,608,275 +$132,537,303 $9.84 92
2022 Q2 50,965,041 $405,682,841 -$30,249,561 $7.96 76
2022 Q1 53,964,373 $523,513,727 +$33,997,944 $9.70 71
2021 Q4 50,239,434 $767,640,710 +$33,441,771 $15.28 56
2021 Q3 48,038,152 $795,758,000 +$3,108,242 $16.60 47
2021 Q2 46,323,514 $984,550,000 +$40,348,386 $21.33 45
2021 Q1 45,681,359 $1,477,378,000 +$1,477,377,994 $32.50 31